Genetic Diseases:?It’s a disease that often strikes people in the prime of life, slowly destroying control over body, mind and personality. It inevitably kills the patient, but usually only after at least a decade of suffering. The underlying cause of Huntington’s disease – a dominant mutation on Chromosome IV – was discovered almost 25 years ago. Now the first trials to target the condition at its source have begun. Chances of finding a cure have never been more realistic.
InflaRx Announces Pricing of Initial Public Offering
Latest NewsGerman inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in total gross proceeds of approximately US$100m.
FDA lifts clinical hold on Cellectis Phase I trials
Latest NewsThe US Food and Drug Administration (FDA) has lifted the clinical hold due to a patient death on Phase I testing of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The hunt for a cure for Huntington’s
BackgroundGenetic Diseases:?It’s a disease that often strikes people in the prime of life, slowly destroying control over body, mind and personality. It inevitably kills the patient, but usually only after at least a decade of suffering. The underlying cause of Huntington’s disease – a dominant mutation on Chromosome IV – was discovered almost 25 years ago. Now the first trials to target the condition at its source have begun. Chances of finding a cure have never been more realistic.
MAB Discovery expands 2013 partnership with BioNTech AG
Latest NewsGerman MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec.
European biotech stocks: New wave of optimism
Latest NewsNousCom raises €42m
Latest NewsSwiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new investor Abingworth. Co-investors include new 5AM Ventures, and existing investors LSP and Versant Ventures.
Designed for sampling.
ProductsAseptic Sample Transfer out of a Closed, Sterile System: due to the Sterisart® Septum Technology.
Blocking antibody recycling vs autoimmune diseases
Latest NewsResearchers at Belgian UCB SA have clinically demonstrated that an antibody targeting a normal cellular recycling process can remove autoantibodies from the blood of people with autoimmune diseases.
Another death related to allogenic CAR-T cell therapy
Latest NewsFollowing the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trials with UCART123, French Cellectis SA’s allogenic CAR-T therapies. Preliminary results from two trials in CD19+ relapsed or refractory B-Cell acute lymphoblastic leukemia patients dosed with UCART19 suggest that cytokine release syndrome (CRS) associated with allogenic CAR-T’s must be managed very carefully.
BioGeneration Ventures Fund III closed at €82m
Latest NewsDutch venture capital company BioGeneration Ventures (BGV) has closed its third fund, BGV III, at €82m exceeding the original target by €32m.